{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,29]],"date-time":"2026-03-29T10:52:24Z","timestamp":1774781544143,"version":"3.50.1"},"reference-count":42,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,23]],"date-time":"2024-01-23T00:00:00Z","timestamp":1705968000000},"content-version":"vor","delay-in-days":22,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["rpthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Research and Practice in Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.rpth.2024.102332","type":"journal-article","created":{"date-parts":[[2024,1,30]],"date-time":"2024-01-30T12:27:44Z","timestamp":1706617664000},"page":"102332","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Anticoagulation in atrial fibrillation and end-stage kidney disease on hemodialysis: a meta-analysis of randomized trials comparing direct oral anticoagulants with vitamin K antagonists"],"prefix":"10.1016","volume":"8","author":[{"given":"Maximilian","family":"Tscharre","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Steiner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Mutschlechner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cihan","family":"Ay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Gremmel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.rpth.2024.102332_bib1","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1093\/eurheartj\/ehz405","article-title":"2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS)","volume":"41","author":"Konstantinides","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.rpth.2024.102332_bib2","first-page":"19","article-title":"2021 European heart rhythm association practical guide on the use of non-vitamin k antagonist oral anticoagulants in patients with atrial fibrillation","author":"Steffel","year":"2021","journal-title":"EP Europace"},{"key":"10.1016\/j.rpth.2024.102332_bib3","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1007\/s00508-018-1381-5","article-title":"Non-vitamin K antagonist oral anticoagulants in patients with an increased risk of bleeding","volume":"130","author":"Gremmel","year":"2018","journal-title":"Wien Klin Wochenschr"},{"key":"10.1016\/j.rpth.2024.102332_bib4","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","article-title":"Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials","volume":"383","author":"Ruff","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.rpth.2024.102332_bib5","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.rpth.2024.102332_bib6","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.rpth.2024.102332_bib7","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.rpth.2024.102332_bib8","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation","volume":"369","author":"Giugliano","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.rpth.2024.102332_bib9","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1056\/NEJMoa1306638","article-title":"Edoxanban versus warfarin for the treatment of symptomatic venous thromboembolism","volume":"369","author":"B\u00fcller","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.rpth.2024.102332_bib10","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1302507","article-title":"Oral apixaban for the treatment of acute venous thromboembolism","volume":"369","author":"Agnelli","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.rpth.2024.102332_bib11","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1056\/NEJMoa1007903","article-title":"Oral rivaroxaban for symptomatic venous thromboembolism","volume":"363","author":"Bauersachs","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.rpth.2024.102332_bib12","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJMoa1113697","article-title":"Extended use of dabigatran, warfarin, or placebo in venous thromboembolism","volume":"368","author":"Schulman","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.rpth.2024.102332_bib13","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0169400","article-title":"Prevalence of atrial fibrillation and antithrombotic therapy in hemodialysis patients: cross-sectional results of the Vienna InVestigation of AtriaL Fibrillation and Thromboembolism in Patients on HemoDIalysis (VIVALDI)","volume":"12","author":"K\u00f6nigsbr\u00fcgge","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.rpth.2024.102332_bib14","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1016\/j.jacc.2016.03.516","article-title":"Pharmacokinetics and pharmacodynamics of dabigatran 75 mg b.i.d. in patients with severe chronic kidney disease","volume":"67","author":"Kooiman","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.rpth.2024.102332_bib15","unstructured":"FDA. Drug Approval Package: PRADAXA (dabigatran etexilate mesylate)."},{"key":"10.1016\/j.rpth.2024.102332_bib16","unstructured":"FDA. Drug Approval Package: ELIQUIS (apixaban)."},{"key":"10.1016\/j.rpth.2024.102332_bib17","unstructured":"FDA. Drug Approval Package: XARELTO (rivaroxaban)."},{"key":"10.1016\/j.rpth.2024.102332_bib18","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1161\/CIRCULATIONAHA.108.816082","article-title":"Impact of proteinuria and glomerular filtration rate on risk of thromboembolism in atrial fibrillation","volume":"119","author":"Go","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.rpth.2024.102332_bib19","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1161\/CIRCULATIONAHA.121.054990","article-title":"Apixaban for patients with atrial fibrillation on hemodialysis: a multicenter randomized controlled trial","volume":"146","author":"Pokorney","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.rpth.2024.102332_bib20","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1002\/rth2.12250","article-title":"Atrial fibrillation in patients with end-stage renal disease on hemodialysis: Magnitude of the problem and new approach to oral anticoagulation","volume":"3","author":"K\u00f6nigsbr\u00fcgge","year":"2019","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.rpth.2024.102332_bib21","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.jacc.2019.10.059","article-title":"Oral anticoagulation for patients with atrial fibrillation on long-term dialysis","volume":"75","author":"Kuno","year":"2020","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.rpth.2024.102332_bib22","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1681\/ASN.2020111566","article-title":"Safety and efficacy of vitamin K antagonists versus rivaroxaban in hemodialysis patients with atrial fibrillation: a multicenter randomized controlled trial","volume":"32","author":"De Vriese","year":"2021","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.rpth.2024.102332_bib23","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1161\/CIRCULATIONAHA.122.062779","article-title":"A\u00a0randomized controlled trial comparing apixaban with the vitamin K antagonist phenprocoumon in patients on chronic hemodialysis: the AXADIA-AFNET 8 study","volume":"147","author":"Reinecke","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.rpth.2024.102332_bib24","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.rpth.2024.102332_bib25","article-title":"Conducting meta-analyses in R with the metafor Package","volume":"36","author":"Viechtbauer","year":"2010","journal-title":"J\u00a0Stat Softw"},{"key":"10.1016\/j.rpth.2024.102332_bib26","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1681\/ASN.2019060579","article-title":"Multicenter randomized controlled trial of vitamin K antagonist replacement by rivaroxaban with or without vitamin K2 in hemodialysis patients with atrial fibrillation: the Valkyrie Study","volume":"31","author":"De Vriese","year":"2020","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.rpth.2024.102332_bib27","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1161\/CIRCULATIONAHA.119.044059","article-title":"Apixaban versus warfarin in patients with atrial fibrillation and advanced chronic kidney disease","volume":"141","author":"Stanifer","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.rpth.2024.102332_bib28","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1056\/NEJMoa1105594","article-title":"Stroke and bleeding in atrial fibrillation with chronic kidney disease","volume":"367","author":"Olesen","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.rpth.2024.102332_bib29","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1161\/CIRCULATIONAHA.112.123992","article-title":"Incident atrial fibrillation and risk of end-stage renal disease in adults with chronic kidney disease","volume":"127","author":"Bansal","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.rpth.2024.102332_bib30","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.ahj.2016.01.010","article-title":"The atrial fibrillation conundrum in dialysis patients","volume":"174","author":"De Vriese","year":"2016","journal-title":"Am Heart J"},{"key":"10.1016\/j.rpth.2024.102332_bib31","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1681\/ASN.2012080841","article-title":"Incidence of stroke before and after dialysis initiation in older patients","volume":"24","author":"Murray","year":"2013","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.rpth.2024.102332_bib32","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1161\/STROKEAHA.115.009095","article-title":"Risk factors of ischemic stroke and subsequent outcome in patients receiving hemodialysis","volume":"46","author":"Findlay","year":"2015","journal-title":"Stroke"},{"key":"10.1016\/j.rpth.2024.102332_bib33","doi-asserted-by":"crossref","first-page":"2984","DOI":"10.1111\/jth.15508","article-title":"Anticoagulation use and the risk of stroke and major bleeding in patients on hemodialysis: From the VIVALDI, a population-based prospective cohort study","volume":"19","author":"K\u00f6nigsbr\u00fcgge","year":"2021","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.rpth.2024.102332_bib34","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.ahj.2016.09.016","article-title":"Vitamin K antagonists for stroke prevention in hemodialysis patients with atrial fibrillation: a systematic review and meta-analysis","volume":"184","author":"Van Der Meersch","year":"2017","journal-title":"Am Heart J"},{"key":"10.1016\/j.rpth.2024.102332_bib35","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.2175","article-title":"Association between use of warfarin for atrial fibrillation and outcomes among patients with end-stage renal disease","volume":"3","author":"Randhawa","year":"2020","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.rpth.2024.102332_bib36","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1016\/j.jacc.2014.09.051","article-title":"Net clinical benefit of antithrombotic therapy in patients with atrial fibrillation and chronic kidney disease","volume":"64","author":"Bonde","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.rpth.2024.102332_bib37","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1177\/10600280211040093","article-title":"A\u00a0review of direct oral anticoagulants in patients with stage 5 or end-stage kidney disease","volume":"56","author":"Starr","year":"2022","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.rpth.2024.102332_bib38","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2023.1261183","article-title":"The safety and efficacy of direct oral anticoagulants among chronic kidney disease patients on dialysis with non-valvular atrial fibrillation: a meta-analysis","volume":"10","author":"Mapili","year":"2023","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.rpth.2024.102332_bib39","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.amjcard.2023.08.116","article-title":"Safety and efficacy of direct oral anticoagulants versus warfarin for atrial fibrillation in end-stage renal disease on hemodialysis: a meta-analysis of randomized control trials","volume":"206","author":"Faisaluddin","year":"2023","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.rpth.2024.102332_bib40","first-page":"29","article-title":"Bleeding risk assessment in end-stage kidney disease: validation of existing risk scores and evaluation of a machine learning-based approach","volume":"122","author":"Nopp","year":"2022","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.rpth.2024.102332_bib41","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1093\/ndt\/gfab060","article-title":"Anticoagulation management in haemodialysis patients with atrial fibrillation: evidence and opinion","volume":"37","author":"De Vriese","year":"2022","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.rpth.2024.102332_bib42","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1111\/ejh.13599","article-title":"Safety of apixaban compared to warfarin in hemodialysis patients: do antiplatelets make a difference?","volume":"106","author":"Ionescu","year":"2021","journal-title":"Eur J Haematol"}],"container-title":["Research and Practice in Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2475037924000190?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2475037924000190?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T12:32:16Z","timestamp":1762864336000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2475037924000190"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["S2475037924000190"],"URL":"https:\/\/doi.org\/10.1016\/j.rpth.2024.102332","relation":{},"ISSN":["2475-0379"],"issn-type":[{"value":"2475-0379","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anticoagulation in atrial fibrillation and end-stage kidney disease on hemodialysis: a meta-analysis of randomized trials comparing direct oral anticoagulants with vitamin K antagonists","name":"articletitle","label":"Article Title"},{"value":"Research and Practice in Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rpth.2024.102332","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Inc. on behalf of International Society on Thrombosis and Haemostasis.","name":"copyright","label":"Copyright"}],"article-number":"102332"}}